Substance Use Disorders
Psychiatric Uses of Gabapentin
by Jon C. Martin, DO, and Danielle Gainer, MD Dr. Martin is with Wright Patterson Medical Center in Wright-Patterson Air Force Base, Ohio. Dr. Gainer is with Wright State University in Dayton, Ohio. Funding: No funding was provided for this article. Disclosures: The authors have no conflicts of interest relevant to the content of this […]
Letter to the Editor: The Ever-changing Landscape of the Opioid Crisis: Fentanyl and its Analogs
By Adegboyega Oyemade, MD, FAPA Funding/financial disclosures. The author has no conflict of interest relevant to the content of this letter. No funding was received for the preparation of this letter. Innov Clin Neurosci. 2018;15(11–12):11–12 Dear Editor: Fentanyl was created in 1960 as an intravenous surgical anesthetic (Sublimaze®, Janssen Pharmaceuticals Inc.), which is 50 to 100 […]
Letter to the editor: Marijuana on the brain— a concern
Dear Editor: Marijuana is one of the most common illegal drugs consumed in the United States. Its use is growing in popularity, especially among young people, partly because of increasing legalization, decriminalization, and the utility of medicinal marijuana. Recreational marijuana differs from medical marijuana in that it has a higher concentration of tetrahydrocannabinol (THC). THC […]
Methadone Treatment of Opiate Addiction: A Systematic Review of Comparative Studies
by Shahid Ali, MD; Barira Tahir, MD; Shagufta Jabeen, MD; and Madeeha Malik Drs. Ali and Tahir are with the Smart Choice Treatment Center in Franklin, Tennessee. Ms. Malik is a Research Associate with the Smart Choice Treatment Center in Franklin, Tennessee. Dr. Jabeen is Site Director of the VA Residency Training Program in Nashville […]
Behavioral and Stereological Analysis of the Effects of Intermittent Feeding Diet on the Orally Administrated MDMA (“ecstasy”) in Mice
by Zeinab Ebrahimian, MSc; Zeinab Karimi, MSc; Mohammad Javad Khoshnoud, Pharm D, PhD; Mohammad Reza Namavar, PhD; Bahram Daraei, PharmD, PhD; and Moshen Raza Haidari, MD, PhD Drs. Ebrahimian and Khoshnoud are with the Department of Pharmacology and Toxicology, Faculty of Pharmacy, Shiraz University of Medical Sciences in Shiraz, IR Iran; Drs. Karimi and Daraei […]
Differential Diagnoses: Encephalopathy or Psychosis?
by Malathi Latha Perugula, MD, and Steven Lippmann, MD The authors are from the Department of Psychiatry and Behavioral Science, University of Louisville School of Medicine, Louisville, Kentucky. Innov Clin Neurosci. 2016;13(11–12):41–42. This column series compares neurological conditions that pose differential challenges in diagnoses. Funding: No funding was provided for the preparation of this article. […]
Letter to the Editor: Gabapentin Abuse in a Patient with Comorbid Mood and Substance Use Disorders
Innov Clin Neurosci. 2016;13(7–8):13–14. Dear Editor: Substance use disorders frequently coexist with and complicate the treatment of mood and anxiety disorders. Gabapentin is one of the most commonly prescribed off-label medications in psychiatric settings.[1] Despite limited evidence, it has been used frequently in the treatment of mood and anxiety disorders in patients with comorbid substance […]
The Neuroscience Report—Vol. 40 (May 6, 2016): Anti-addiction Medications
The latest in neuroscience—sorted and summarized for you Welcome to The Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to 5 journal articles, 5 news articles, and 5 wildcard picks. Brought to you by Innovations in Clinical Neuroscience—your source for peer-reviewed, evidence-based information. This week’s […]
Why Not Pot? A Review of the Brain-based Risks of Cannabis
by Kai MacDonald, MD, and Katherine Pappas, BA Dr. MacDonald and Ms. Pappas are with UC San Diego Psychiatry, San Diego, CA, USA Innov Clin Neurosci. 2016;13(3–4):13–22. Funding: Dr. MacDonald’s work is sponsored in part by the Goodenough Neuroscience Research Fund. Financial disclosures: The authors have no conflicts of interest relevant to the content of […]
When the Opioid Medications Go Missing: Confidentiality and Safety in Adolescents
by Muhammad Hassan Majeed, MD Dr. Majeed is an Attending Psychiatrist at Natchaug Hospital, Norwich, Connecticut. Innov Clin Neurosci. 2017;14(5–6):25–27 Funding: No funding was received for the preparation of this article. Financial Disclosures: The author has no conflicts of interest relevant to the content of this article. Keywords: Opioids, diversion, safety, confidentiality, adolescents Abstract: Patients receiving […]
Continue Reading